Alvotech (ICE:ALVO)

Market Cap	198.25B -63.8%
Revenue (ttm)	69.62B +45.6%
Net Income	8.44B
EPS	29.16
Shares Out	n/a
PE Ratio	23.49
Forward PE	23.71
Dividend	n/a
Ex-Dividend Date	n/a

Volume	8,710
Average Volume	97,528
Open	618.00
Previous Close	620.00
Day's Range	612.00 - 620.00
52-Week Range	554.00 - 1,830.00
Beta	0.11
RSI	44.81
Earnings Date	Mar 18, 2026

About Alvotech

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company’s lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory cond...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2013
• Employees: 1,012
• Stock Exchange: Nasdaq Iceland
• Ticker Symbol: ALVO

Financial Performance

In 2024, Alvotech's revenue was $491.98 million, an increase of 426.84% compared to the previous year's $93.38 million. Losses were -$231.86 million, -57.98% less than in 2023.

Financial numbers in USD